| Business Summary | | Generex
Biotechnology
is
engaged
in
the
research
and
development
of
drug
delivery
systems
and
technology.
The
Company
is
a
development
stage
company.
To
date,
the
Company
has
devoted
a
substantial
majority
of
its
efforts
and
resources
in
developing
a
technology
to
orally
administer
large
molecule
drugs,
including
proteins,
hormones,
peptides,
vaccines
and
other
pharmaceutical
products.
The
initial
application
of
the
Company's
large
molecule
drug
delivery
technology
is
an
oral
insulin
formulation
for
use
in
the
treatment
of
diabetes.
The
formulation
is
sprayed
into
the
mouth
using
a
hand-held
aerosol
applicator. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Generex
Biotechnology
is
primarily
engaged
in
the
development
of
a
proprietary
drug
delivery
platform
technology
to
orally
administer
large
molecule
drugs
which,
historically,
have
been
administered
by
injection.
For
the
nine
months
ended
4/30/01,
revenues
totaled
$1
million,
up
from
$0.
Net
loss
totaled
$18.1
million,
up
from
$6.3
million.
Results
reflect
$1
million
received
in
connection
with
the
Eli
Lilly
agreement,
offset
by
increased
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| E. Mark Perri, 39 Chairman,
CFO | $103K | Anna Gluskin, 49 Pres,
CEO | 105K | Rose Perri, 33 COO,
Sec., Treasurer | 97K | Pankaj Modi, Ph.D., 46 VP
of R&D | -- | Dollar amounts are as of 31-July-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|